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Abstract
Background: Universities are significant contributors to research and technologies in health; however, the health
needs of the world’s poor are historically neglected in research. Medical discoveries are frequently licensed
exclusively to one producer, allowing a monopoly and inequitable pricing. Similarly, research is often published in
ways that make it inaccessible. Universities can adopt policies and practices to overcome neglect and ensure
equitable access to research and its products.
Methods: For 25 United Kingdom universities, data on health research funding were extracted from the top five
United Kingdom funders’ databases and coded as research on neglected diseases (NDs) and/or health in low- and
lower-middle-income countries (hLLMIC). Data on intellectual property licensing policies and practices and open-
access policies were obtained from publicly available sources and by direct contact with universities. Proportions of
research articles published as open-access were extracted from PubMed and PubMed Central.
Results: Across United Kingdom universities, the median proportion of 2011–2014 health research funds
attributable to ND research was 2.6% and for hLLMIC it was 1.7%. Overall, 79% of all ND funding and 74% of
hLLMIC funding were granted to the top four institutions within each category. Seven institutions had policies to
ensure that technologies developed from their research are affordable globally. Mostly, universities licensed their
inventions to third parties in a way that confers monopoly rights. Fifteen institutions had an institutional open-
access publishing policy; three had an institutional open-access publishing fund. The proportion of health-related
articles with full-text versions freely available online ranged from 58% to 100% across universities (2012–2013);
23% of articles also had a creative commons CC-BY license.
Conclusion: There is wide variation in the amount of global health research undertaken by United Kingdom
universities, with a large proportion of total research funding awarded to a few institutions. To meet a level of
research commitment in line with the global burden of disease, most universities should seek to expand their
research activity. Most universities do not license their intellectual property in a way that is likely to encourage
access in resource-poor settings, and lack policies to do so. The majority of recent research publications are
published open-access, but not as gold standard (CC-BY) open-access.
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Background
Universities are significant contributors to the research
and development of medicines, and other health prod-
ucts central to global health; for example, a third of
innovative medicines registered in the United States of
America were developed in universities [1]. In the
United Kingdom, universities are important contributors
to research globally [2, 3]. In 2013, 26% of all research
and development (R&D) in the United Kingdom (by
total funding across sectors) was carried out in higher
education institutions [4]. The investments in the United
Kingdom Research Excellence Framework in 2015 high-
lights an overall desire for evaluation of research output
from United Kingdom universities [5]. In addition, uni-
versity research will be a crucial component to any strat-
egy to increase R&D in the area of global health, such as
that proposed by the Consultative Expert Working
Group on Research and Development of WHO [6].
Braveman, writing on equity in global health in 1996,
defined equity as “[meaning] that people’s needs, rather
than social privileges, guide the distribution of opportun-
ities for well-being” [7]. Given that the aim of research is
to improve these ‘opportunities for well-being’ in a par-
ticular health area, needs-guided distributive decisions
are required both in health research funding and in the
management of the outputs of research in order for
health research systems to be equitable. Accordingly, an
equitable system of research and development in health
would include (among others) needs-driven research
funding that addresses the global burden of disease,
commitments to share research findings, and commit-
ments to making the end products of research afford-
able. To assess the status quo of United Kingdom
universities with regard to these facets, we chose to
measure research grant distribution as a proxy for re-
search activity, open-access publishing activity to address
the sharing of research findings, and the management of
intellectual property owing to its close link to end-
product affordability.
The Commission on Health Research and Develop-
ment in 1990 found that only 5% of research spending is
on health issues affecting developing countries, where
93% of the disease burden occurred. Reducing this im-
balance, they reported, is an “essential link to equity in
development” [8]. While their recommendations fo-
cussed primarily on research capacity strengthening in
developing countries, focus in the last decade has ex-
panded to how research policy and institutions in high-
income countries could change in order to address this
imbalance [6, 9]. Empirically, while poverty-related dis-
eases represent 14% of the global disease burden, world-
wide only 1.3% of health R&D expenditure is devoted to
this area [10]. In the United Kingdom, a 2015 report by
the All-Party Parliamentary Group on Global Health
discussed the United Kingdom’s overall contributions to
global health and recognised an imbalance between the
global burden of diseases and the funding allocated to
researching these [3].
The approach universities take to managing intellec-
tual property that results from their research affects the
affordability of end products (e.g. medicines, vaccines,
diagnostics). Competitive generic production has been
shown to achieve rapid price decreases and was instru-
mental to the global scale-up of HIV treatment [11].
Universities can facilitate equitable access to the fruits of
their research by adopting socially responsible licensing
(SRL) policies to promote early generic manufacture of
medicines, or other mechanisms to promote affordabil-
ity, in low- and middle-income countries (LMICs) [12].
The WHO Consultative Expert Working Group on Re-
search and Development included SRL (termed ‘equit-
able licensing’ in their report) in their recommendations
for improving the system of research and development
to address unmet global needs, and SRL is now regarded
as standard practice across universities in North Amer-
ica [12–14]. In the United Kingdom, a recent report by
the All-Party Parliamentary Group on Global Tubercu-
losis recommended that “SRL should be adopted by aca-
demic institutions in the right circumstances” and “[t]he
UK government should […] conduct a study into how
SRL could be implemented across […] publicly funded re-
search” [15].
Open-access publication is important in making re-
search accessible globally, particularly in LMICs [16].
The term ‘open access’ is used to describe a range of
publishing practices, within which the scope of accessi-
bility varies.1 For example, among the academic articles
for which full texts are freely available online, only some
will have a creative commons CC-BY license – that is,
many articles will be copyrighted in ways that restrict
their use, reproduction and distribution. The gold stand-
ard of open access publishing requires using a CC-BY
license [17].
This study measured global health research funding,
and research sharing policies and practices of 25 top-
funded United Kingdom universities, to provide an over-
view of current United Kingdom university research prac-
tices pertaining to global health.
The United Kingdom university global health research
league table
This study began as a project run in collaboration
between two student-run non-profit organisations –
Medsin-UK and Universities Allied for Essential Medi-
cines United Kingdom (UAEM UK). Some of the data in
this paper have been published as an interactive website
at www.globalhealthgrades.org.uk. Data analysis for the
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online version follows an adapted methodology, available
under the Methodology tab.
Methods
This study included the 25 United Kingdom universities
receiving the most Medical Research Council (MRC)
funding in 2010–2011 (the most recent year with pub-
licly available data at the time of beginning the study)
[18];2 25 was selected as a cut-off for feasibility. Metrics
used divide into two sections: research funding and
research sharing practices.
Research funding
For each university, we measured the proportion of total
health research funding (THRF) that was attributable to
research on two overlapping areas of research, namely
neglected diseases (NDs) and health in low- and lower-
middle-income countries (hLLMICs). These overlapping
categories were used to increase the ability to represent
‘global health’ in our measures, in recognition that
‘global health’ is a broad area of study, which would not
be adequately represented by either category alone.
Research on health in low- and lower-middle-income
countries (LLMICs) was defined as research for which
both (1) the subject of inquiry is primarily in a country, or
countries, in the low- or lower-middle-income brackets,
and (2) the subject of inquiry is an aspect of human
health, defined as belonging to any one or more of the
‘research for health’ categories described by the Global
Forum for Health Research, which include biomedical
research, research into health policy and systems research,
behavioural and social science, and operational research
[19]. Countries were classified as low-income or lower-
middle-income according to the 2012 World Bank criteria
(Additional file 1) [20].
NDs were defined as diseases listed as neglected in the
G-FINDER 2011 survey on global ND innovation fund-
ing [21]. This list includes HIV/AIDS, malaria, tubercu-
losis, diarrhoeal diseases, dengue, kinetoplastid and
helminth infections, bacterial pneumonia and meningi-
tis, salmonella infections, leprosy, rheumatic fever,
trachoma, and Buruli ulcer (Additional file 1). The G-
FINDER survey defines diseases as ‘neglected’ based on
three criteria; namely, the disease disproportionately
affects people in developing countries, there is a need
for new products, and there is a market failure in R&D
for the disease [21]. To our knowledge, the G-FINDER
survey (funded by the Bill & Melinda Gates Foundation)
is the only prominent survey of research funding that
focuses on NDs [9].
To calculate THRF by university, data on health re-
search grants provided by the five major funders of
research in the United Kingdom were collected from the
respective funders’ databases, including the United
Kingdom Department for International Development
(DfID) [22], the European Commission (EC) [23], the Bill
& Melinda Gates Foundation [24], MRC [25], and Well-
come Trust [26]. Data were extracted from these data-
bases (links in references) by using their respective
websites’ advanced search functions, and downloading
results as a spreadsheet where possible or manually tran-
scribing if not. In the online search function, a timeframe
of July 1, 2011, to December 31, 2013, was used. Search
restrictions of ‘research grant’ and ‘university’ as grant re-
cipient were used for MRC, Bill & Melinda Gates Founda-
tion and Wellcome Trust. EC and DfID have a broader
funding remit beyond health, therefore, in order to ensure
representative data, not all grants were extracted from the
database. For EC, only those grants labelled in the
database with a subject related to health, medicine or life
sciences were included. For DfID, only those grants
classed within the theme of ‘health’ were included. While
these five funders do not yield a comprehensive dataset of
all health research grants given in the United Kingdom,
they are likely to represent the great majority of global
health research, representing about 90% of infectious
disease research investments in 2010 [27].
Extracted data on research grants were filtered by uni-
versity, and manually coded as meeting the criteria for re-
search on NDs or hLLMICs, as defined above, or neither.
Where multiple collaborator institutions were named on a
grant, because the databases used do not state the exact
amount awarded to each collaborator, the full amount of
the grant was attributed to the ‘lead’ institution. An excep-
tion to this was the EC database, where the exact amount
awarded to collaborators was available: for EC grants, we
counted the amount awarded to the lead institution only.
While the areas of research we defined as ‘ND’ or
‘hLLMIC’ overlap, a choice in coding was forced between
the two at the discretion of the reviewer. For each univer-
sity, we calculated the total funding received for research
into NDs and hLLMICs, and the proportion this funding
represented of total health research funding received from
the five funders given above.
Primary data collection and coding of all extracted
grant descriptions were performed independently by two
reviewers, each blinded to the selection of the other.
Coding for each search result was compared and dis-
agreements resolved by consensus.
No adjustments were made for inflation. EC and Gates
Foundation grants, reported in the databases in EUR
and USD, respectively, were converted to GBP using the
average exchange rate over 2011–2014 [28].3
Research sharing: patents and open access
This section assessed university patenting and licensing
of health-related technologies, and open access publica-
tion practices. ‘Technology transfer office’ (TTO) is a
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generic term used to describe the office or entity within
a higher education institution that manages intellectual
property associated with the institution. ‘Health-related
technologies’ include, for example, medicines, vaccines
and diagnostics. Data were collected by self-reporting by
TTOs or their equivalent, via responses to an online
questionnaire and/or a request for information made
under the United Kingdom Freedom of Information Act
2000 (FOI) (Additional file 2).
TTOs were first sent an online questionnaire by email
with reminders sent a minimum of four times by email
and two times by telephone over a 12-week period be-
ginning July 6, 2014. FOI requests were then sent to
universities that did not respond fully by the end of the
12-week period, seeking the same information as the
online survey. We designed FOI requests in recognition
of the fact that our requested data could be held by
TTOs in a variety of formats – the wording of the FOI
request was thus slightly different to the survey. The
FOI requests also contained an invitation to complete
the original online survey, thus removing the need for
providing information through the FOI process.
The following data were extracted from responses:
 The percentage of the university’s health technology
licensing contracts signed in the last year that were
non-exclusive
 The percentage of all health technologies in the past
year for which patents were sought in LMICs4
 The percentage of the university’s health technology
licensing contracts signed in the past year that
included provisions to promote access to the
technologies in LMICs (this was assessed from
survey responses only)
Systematic searches of university websites and public
databases were also conducted so that, where possible,
findings could be validated by more than one source.
Primary data collection and coding was performed
independently by at least two researchers, each blinded
to the coding of the other. Where coding differed, a
decision was reached by consensus.
To assess university commitment to SRL, we systemat-
ically searched the university’s website using the web-
site’s search engine, supplemented by a similar search in
the Google search engine, using the following terms:
“[university name]”, “global access licensing”, “socially
responsible licensing”, “equitable access licensing”, “ac-
cess to medicines”, “university licensing”, “technology
transfer”. We supplemented this search by reviewing the
list of signatories to Stanford University’s ‘Nine Points to
Consider in Licensing University Technology’ and the
‘Statement of Principles for the Equitable Dissemination
of Medical Technologies’ [14, 29], and by the inclusion
of a relevant question in the survey mentioned above
(question 2, Additional file 2). Statistical correlation was
calculated for the presence of an SRL policy versus the
percentage of licenses that were non-exclusive, as well as
for the percentage of licenses containing access provi-
sions versus percentage that were non-exclusive, using
Somers’ D test.
University commitments to promoting open-access
publication were assessed by two independent reviews
of the page, if one existed, of the university website,
that outlined their policy on open access publication.
We supplemented this search by reviewing the list of
signatories to the Compact for Open-Access Publish-
ing Equity [30] and the list of institutions listed in
the Registry of Open Access Repositories Mandatory
Archiving Policies [31]. These databases provide lists
of universities that have open access publication
funds, and an institutional open-access publishing
mandate and/or policy, respectively. We measured the
proportion of research articles published as ‘free-ac-
cess’, which signifies academic publications for which
full-text versions are freely available online, but might
have limited re-use rights [32], and the proportion
published as CC-BY.
We calculated the percentage of each university’s
health-related research output for which the full text
is freely available online within 1 year of publication
(free access). Percentages were calculated by dividing
the number of citations affiliated to a university in
PubMed Central (PMC) by the number of citations
affiliated to it in PubMed. PMC indexes only publica-
tions for which full-text versions are freely available,
while PubMed indexes publications without this re-
striction. PMC results can, in practice, be considered
a subset of PubMed that are freely available as full-
text versions [33].
We used the following filters: “type – journal article”
(PubMed only); “affiliation – (university name)”; “publi-
cation date: 1/8/20121/8/2013”. 5 A second search was
done using a “cc-by license” filter in PMC to determine
the proportion of articles in the PMC subset that used a
CC-BY license.
Statistical analysis
Results with a value greater than the upper quartile plus
1.5 times the interquartile range were considered out-
liers. Statistical tests were run on data from which out-
liers had been removed; for ND-attributable funding,
London School of Hygiene and Tropical Medicine
(LSHTM) and the University of Reading were excluded;
for hLLMIC-attributable funding, LSHTM and the Uni-
versity of Leeds were excluded (Table 1). Spearman’s
rank correlation coefficient (r) was used to test correla-
tions of proportional ND-/hLLMIC-attributable funding
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to THRF (Table 1), to test correlations between ND-/
hLLMIC-attributable funding and licensing and open-
access publishing practices (Additional file 3), and to test
correlations between THRF and publishing practices.
Somers’ D test (rank-biserial) was used to assess correla-
tions given in Table 3. All statistical tests were run using
Small Stata software version 10.0, except Somers’ D,
which was calculated using SPSS version 21.
Results
Research funding
For the 3-year period 2011–2014, we identified a THRF
of £1.9 billion granted to the 25 institutions included in
this study, of which £128 million were to research on
NDs and £71 million were to research on hLLMICs,
equivalent to 6.7% and 3.7% of THRF, respectively.
Across institutions, the median proportion of THRF
Table 1 Funding for research on neglected diseases and health in low- and lower-middle-income countries
University Funding attributable to research on
neglected diseases, £ (percentage of THRF
in brackets)
Funding attributable to research on
health in LLMICs, £ (percentage of THRF
in brackets)
Total health research
funding in 2011–2014, £
(THRF)
Cardiff University 0 (0.0) 126,286 (0.3) 48,883,350
Imperial College 17,826,708 (11.0)a 5,542,297 (3.40) 162,093,401a
King’s College London 2,676,930 (2.4) 6,205 (0.0) 110,854,979
LSHTM 24,383,502 (32.5)a 22,883,802 (30.5)a 74,970,446
Newcastle University 0 (0.0) 517,735 (0.9) 59,051,690
Queen Mary 625,257 (2.7) 584,374 (2.5) 23,404,007
University College London 6,321,359 (2.6)a 7,895,999 (3.2)a 245,303,666a
U. of Aberdeen 0 (0.0) 507,154 (2.4) 20,816,124
U. of Birmingham 2,808,451 (8.0) 1,464,820 (4.2) 35,067,638
U. of Bristol 589,409 (1.3) 0 (0.0) 44,036,199
U. of Cambridge 688,439 (0.3) 3,085,230 (1.2) 260,465,308a
U. of Dundee 5,980,568 (7.2) 301,480 (0.4) 82,629,476
U. of Edinburgh 4,744,693 (3.8) 3,041,556 (2.4) 125,460,071
U. of Glasgow 1,632,483 (3.9) 0 (0.0) 41,556,952
U. of Leedsb 0 (0.0) 7,500,000 (23.3)a 32,221,557
U. of Leicester 4,000 (0.0) 0 (0.0) 16,756,360
U. of Liverpool 3,540,839 (10.8) 756,015 (2.3) 32,858,179
U. of Manchester 440,484 (0.6) 0 (0.0) 69,608,229
U. of Nottingham 673,835 (3.1) 366,123 (1.7) 21,946,156
U. of Oxford 51,697,856 (17.6)a 14,028,309 (4.8)a 293,780,277a
U. of Reading 1,130,489 (19.6) 0 (0.0) 5,778,531
U. of Sheffield 0 (0.0) 0 (0.0) 28,309,890
U. of Southampton 0 (0.0) 548,557 (6.8) 8,056,867
U. of Sussex 1,558,982 (4.0) 111,824 (0.3) 39,160,020
U. of Warwick 299,060 (1.7) 1,477,190 (8.3) 17,810,933
Total 127,623,343 (6.71) 70,744,957 (3.72) 1,900,880,305
Median proportion across
institutions
2.6 (IQR 7.2) 1.7 (IQR 3.4) N/A
Share of total within-column
funding granted to top four
institutions
79% 74% 51%
Correlation with THRF 0.390 (P = 0.066) 0.074 (P = 0.736) N/A
LLMICs low- and lower-middle-income countries, LSHTM London School of Hygiene and Tropical Medicine, IQR inter-quartile range, THRF total health
research funding
aValues for top four institutions by absolute funding within each column
bAll hLLMIC-attributed funding at the University of Leeds (£7.5 million) represents a single grant awarded by DfID
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attributable to NDs and hLLMICs was 2.6% (IQR 7.2%)
and 1.7% (IQR 3.4%), respectively (Table 1). Proportional
ND/hLLMICs research funding for individual universities is
shown in Figures 1 and 2, respectively. Proportional
funding for research on NDs or hLLMICs did not correlate
significantly with the THRF of the institution (NDs: r =
0.390, P = 0.066; hLLMICs: r = 0.074, P = 0.736).
The top four institutions by absolute funding (indicated
in Table 1) were responsible for 79% and 74% of total ND
and total hLLMIC research funding granted to all 25 insti-
tutions, respectively. The top four by absolute funding
were not the same as the top four by proportional funding.
For the time frame 2011–2014, we found that six
universities had no ND-attributable research funding, and
six universities had no hLLMIC-attributable research
funding.
There was significant variability between relative
contributions by funders to THRF, ND-attributable, and
hLLMIC-attributable research funding (Additional file
4). Wellcome Trust and the MRC were responsible for
far larger proportions of funding of United Kingdom
university health research, in general, than the EC, DfID,
or the Gates Foundation. In funding for ND research,
the Gates Foundation contributed nearly as much as the
Wellcome Trust and the MRC, while EC and DfID
contributions remained lower. In funding for hLLMICs
research, DfID contributed the greatest amount, with
slightly lower contributions by Gates Foundation, MRC
and the Wellcome Trust. Funding contributions were
more even between funders in hLLMIC research funding
than they were in total health research funding or ND
research funding.
Three-year trends are shown in Additional file 4.
Trends in THRF show mixed year-on-year funding
changes. The University of Oxford and the University
of Newcastle show an upward trend, while King’s
College London and LSHTM show a downwards
trend. All other universities show unclear trends over
3 years. In ND research funding, upwards funding
trends were seen for the University of Oxford, Imper-
ial College London, University College London (UCL),
the University of Edinburgh, the University of Birming-
ham, and the University of Glasgow. LSHTM showed a
downwards trend. In hLLMICs research, trends were un-
clear, except for LSHTM, which showed a downwards
trend.
Licensing of patented technologies
Seven of the 25 universities had public commitments to
making the products of their research affordable in de-
veloping countries through SRL policies (Table 2). In the
20 universities that licensed health technologies within
the last year, approximately 30% of all licenses were
non-exclusive. Four universities reported licensing 81–
100% of licenses non-exclusively, while 11 reported
licensing 0–20% non-exclusively (Table 3). Two univer-
sities reported including access provisions in 81–100%
of licenses, whereas 19 reported including these in
0–20% of licenses (Table 2).
The presence of an SRL policy at a university posi-
tively predicted the level of non-exclusive licenses as
well as the use of access provisions in exclusive licenses,
though neither of these relationships was statistically sig-
nificant (Table 3). In general, levels of patent seeking in
LLMICs and BRICS countries were very low. It was
more common for patents to be sought in BRICS coun-
tries than in other LLMICs (Additional file 3).
Neither absolute nor proportional ND or hLLMIC
funding showed statistically significant correlation to li-
censing practices (Additional file 3).
Fig. 1 Proportion of total health research funding attributable to
research on neglected diseases in 2011–2014
Fig. 2 Proportion of total health research funding attributable to
research on health in low- and lower-middle-income countries
in 2011–2014
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Open access publishing
We differentiate between institutional open-access pub-
lishing funds – funds offered by the university to cover
open-access publication fees (article processing charges)
– and open-access publishing funds offered to re-
searchers by extra-institutional bodies such as the Well-
come Trust’s Charity Open Access Fund and Research
Councils UK’s open access block grants. All 25 univer-
sities included in the study were recipients of Charity
Open Access Fund and/or Research Councils UK open-
access publishing funds [34, 35]. Institutional funds,
however, were found in only three institutions (Table 4).
Institutional open access policies were found in 15 uni-
versities (Table 4).
Of health-related research articles published by the
universities surveyed in 2012–2013, 76% had full texts
freely available online. The proportion of individual uni-
versities’ total health-related publications that were free-
access in 2012–2013 ranged from 58% to 100%, with a
slight negative skew and a median of 75% (IQR, 16%);
23% (IQR, 7%) of publications were free-access and had
a CC-BY license, which allows for unrestricted distribu-
tion and re-use of content. Figure 3 shows the propor-
tion of total journal articles published in 2012–2013
published as free-access and CC-BY for each university.
No correlation was found between THRF and propor-
tion published as free-access (r = 0.287, P = 0.164) or
between THRF and proportion published as CC-BY (r =
Table 2 Overview of intellectual property licensing policy landscape
University Has publicly committed
to general principles of SRL
Plans to endorse








University College London Yes N/A Yes No
University of Edinburgh Yes N/A Yes No
University of Manchester Yes N/A Yes No
University of Oxford Yes N/A No No
Imperial College London Yes N/A No No
University of Dundee Yes N/A No No
University of Bristol Yes N/A No No
LSHTM No Yes No No
University of Liverpoola No Yes No No
University of Aberdeen Nob No No No
University of Nottingham Nob No No No
University of Sussex Nob No No No
University of Birmingham No No No No
University of Cambridge No No No No
Cardiff University No No No No
University of Glasgow No No No No
King’s College London No No No No
University of Leeds No No No No
University of Leicester No No No No
Newcastle University No No No No
Queen Mary No No No No
University of Reading No No No No
University of Sheffield No No No No
University of Southampton No No No No
University of Warwick No No No No
Data from systematic website searches (policies only), self-reporting via electronic survey, and responses to requests for information made under the Freedom of
Information Act 2000 (practices only)
SRL socially responsible licensing, LSHTM London School of Hygiene and Tropical Medicine
aPolicies on intellectual property management in effect at the University of Liverpool do not affect the management of intellectual property at the Liverpool
School of Tropical Medicine, the latter of which is not included in this study
bResponses to surveys indicated general commitment to principles of SRL by the technology transfer office, but this commitment was not official or public at the
time of data collection
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0.034, P = 0.873). The percentage of articles published as
free-access and percentage published as CC-BY were
statistically correlated (r = 0.643, P = 0.0005). Propor-
tional hLLMIC research funding was moderately corre-
lated to both proportion of articles published as free-
access (r = 0.588, P = 0.004) and CC-BY (r = 0.491, P =
0.02) (Additional file 3). Absolute hLLMIC funding, and
absolute and proportional ND funding were not signifi-
cantly correlated to open-access publishing practices.
There were two institutions (LSHTM, Leicester) for
which the number of publications in PMC exceeds that in
PubMed, resulting in a free-access percentage of greater
than 100%. This is likely a result of the slight differences
in the types of literature that are included in the two
different databases [33]. Advanced search functions also
differ slightly. Consequently, while the percentage values
presented in Fig. 3 can be used for the comparison of
universities, their interpretation as absolute measures of
publication practices is limited at this stage.
Discussion
A number of trends have been demonstrated: a signifi-
cant gap in funding for global health research, disparities
between institutions’ level of commitment, and irregular
adoption of research sharing policies and practices by
United Kingdom universities.
The low median proportion of funding given to
LLMIC health and ND research shows that most univer-
sities are carrying out less research into these areas than
would be expected if funding of research were equivalent
Table 3 Overview of licensing practices (2012–2013)
University Publicly available SRL
policy
Proportion of licenses that were
non-exclusive
Proportion of licenses that included provisions to
promote access in LLMICs
University of Bristol Yes 96% 44%
Newcastle University No 90% –
University of Leeds No 82% –
University of Oxford Yes 71–100% 81–100%
University College London Yes 51–70% 41–60%
University of Glasgow No 51–70% 0–20%
University of Edinburgh Yes 31–50% 0%
Imperial College London Yes 31–50% 21–40%
University of Leicester No 11–30% 0–20%
University of Sheffield No 11–30% 0–20%
University of Aberdeen No 0–10% 81–100%
University of Birmingham No 0–10% 0–20%
University of Manchester Yes 0–10% 0–20%
University of Sussex No 0–10% 0–20%
University of Southampton No 9% –
University of Dundee Yes 0% –
King's College London No 0% –
University of Nottingham No 0% –
Queen Mary No 0% –
University of Warwick No 0% –
Cardiff University No N/A N/A
University of Liverpool No N/A –
LSHTM No N/A N/A
University of Reading No N/A N/A
University of Cambridge No a –
Correlation with presence of
SRL policy
– 0.469 (P = 0.051) 0.286 (P = 0.346)
Correlations given as Somers’ D, calculated from datasets with ‘N/A’,’—‘, and ‘a’ values censored
‘N/A’ indicates no licenses were executed during the time period
‘–’ indicates that this question was not answered via electronic survey, and could not be ascertained otherwise
SRL socially responsible licensing, LSHTM London School of Hygiene and Tropical Medicine, LLMICs low- and lower-middle-income countries
aRefused to provide information requested under the Freedom of Information Act for this question
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to the proportion of global burden of disease attributable
to these categories. The median proportion of total
health research funding devoted to NDs at United King-
dom universities (2.6%) is approximately five times lower
than the global burden of NDs, where NDs are defined
by the G-FINDER list (13.8% of the global burden of dis-
ease) [10, 21]. Overall ND funding identified totalled
6.7% of all health research funding identified, that is,
about half the global burden of disease. For three univer-
sities – LSHTM, the University of Reading and the Uni-
versity of Oxford – the proportion of total research
funding for research on NDs exceeded the 13.8% thresh-
old (Fig. 1). In terms of ‘equity’ as fulfilled by distributive
decisions based on need, this translates to United King-
dom university research being ‘halfway’ to a proportional
distribution of ND research funding that could be called
equitable. Indeed, it can be argued that, for an equitable
funding distribution to be reached, considering historical
underfunding, ND research funding would, for a period
of time, need to be significantly greater than the corre-
sponding global burden of disease in order to ‘catch up’.
The median proportion of research funding devoted to
hLLMIC research at United Kingdom universities is
1.7% and overall United Kingdom hLLMIC funding of
all health funding is 3.7%, which is 1.5 and 1.8 times less
than for ND research, respectively. LLMICs account for
59% of the global burden of disease (measured in
disease-adjusted life years; authors’ own calculation
using http://vizhub.healthdata.org/gbd-compare/). The
category of ‘research on hLLMICs’ is not as well-
established as that of NDs; our definition was based on
the grant specifically mentioning a focus on one or more
developing countries. It is likely that, in many cases, re-
search on health issues affecting mainly developing
countries may be described in the grant only in terms of
the health issue itself and not its geographical relevance.
Our findings regarding hLLMIC research funding are
thus meant to complement findings on NDs, although
they cannot be directly comparable to figures for global
burden of disease in the way that ND figures can.
The top four institutions by absolute funding represent
79% of total ND research funding and 74% of total
hLLMIC research funding. This inter-institutional in-
equality is greater than inter-institutional inequality in
total health research funding, where the top four institu-
tions by absolute funding received 51% of all funding.
The notable concentration of neglected disease and
LLMIC health research funding in a few universities has
a number of possible explanations. It may be that these
areas of work are tacitly considered specialist areas –
and thus a few specialist centres emerge. Alternatively, it
may be that these academic areas – as areas of historical
neglect – require ‘confidence’ to engage in, that is, an
institution has to be relatively large and well-funded in
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aFunds other than those provided by the Wellcome Trust/Charity Open Access
Fund or Research Councils UK. All 25 universities included in the study were
recipients of Charity Open Access Fund and/or Research Councils UK open-
access publishing funds
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order to enter these areas of research that have historic-
ally been less prestigious, and traditionally considered
less profitable. Three-year funding trends reflect both
the dominance of a small number of institutions in both
ND and hLLMIC research, as well as the greater inter-
institutional inequality in these areas than in THRF
(Additional file 4). The degree of inter-institutional in-
equality did not seem to change across the 3 years in
THRF, ND or hLLMIC funding, though this was not sta-
tistically tested. The trends also demonstrate irregularity
in funding – this may be due to the commonality of a
low number of individual multi-million grants (as op-
posed to a larger number of smaller grants). Our meth-
odology has counted the grant in the year it was
awarded (or the start year for the project, depending on
the database), instead of spreading the grant money over
the whole time of the project. Although this is a limita-
tion of time-trend analysis, we do not see this as a
significant limitation for the main aim of this analysis –
to provide a ‘snapshot’ overview of funding.
Analysis of proportional funding – ND/hLLMIC fund-
ing as a proportion of the institution’s THRF – paints a
different picture to absolute ND/hLLMIC funding: many
universities with extensive total health research funding
rank relatively low when universities are ordered by
proportional funding. For example, only 0.3% of research
funding at the University of Cambridge (THRF £260
million) were attributable to ND research; at UCL
(THRF £245 million), only 2.6% were attributable to ND
research – placing both multiple ranks below universities
with far smaller THRF, such as the Universities of
Birmingham, Dundee and Reading (Fig. 1). Similarly, in
hLLMIC research, the Universities of Leeds, Warwick and
Southampton rank numerous places above Edinburgh and
Cambridge (Fig. 2). In some cases, this is due to a com-
paratively small number of large grants summated repre-
senting a significant portion of a smaller universities’
THRF.6
In general, the high variability of proportional funding
across leading universities in the United Kingdom points
to a lack of consistent commitment to these research
areas (Figs. 1 and 2). The finding that current work is
concentrated in the top institutions may inform a policy
debate on whether to support this trend or promote a
‘standard minimum threshold’ of research into neglected
areas at all institutions. There are numerous examples of
smaller and less well-funded universities that are ‘pulling
more than their weight’, committing to a neglected
research area, and simultaneously, numerous examples
of large institutions with comparatively little commit-
ment to global health research. A discrepancy between
the funding of research on individual neglected tropical
diseases and their relative disease burdens has also been
described [2].
Following Braveman’s framework, equity requires fo-
cussed, systemic changes in resource allocation. Systemic
change in United Kingdom research could manifest as
either commitment to a (higher) median level of ND
and hLLMIC research investment across institutions, or
intentional ‘delegation’ of the work to a smaller number
of institutions: either approach would be consistent with
progress towards equity. It is likely that, while the
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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Fig. 3 Free-access and CC-BY publications as percentage of total health-related publications, 2012–2013
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‘higher median’ approach could come primarily from
decisions taken by individual universities, a ‘delegation’
approach to systemic change would have to come from
decisions by funders. Nothing precludes both ap-
proaches from being taken simultaneously. Funders and
researchers are interdependent in setting the research
agenda: funders cannot fund research in areas where
there are no researchers, and researchers cannot do
research in areas where there is no funding.
Overall, investments in ND and hLLMIC research in
the United Kingdom are at less than half the levels that
would expected to match global disease burden. To over-
come this mismatch, there is a need for funders of United
Kingdom university research to prioritise neglected areas
of research in the grant programmes they offer, and for
universities to prioritise this research internally.
Monopolies permitted by patent rights have led to
prices that exclude the developing world from access, for
example, in HIV/AIDS, hepatitis C, and cancer medicines
[36–38]. That this is inequitable is obvious, as there is no
lack of need for these medicines in poorer countries. Re-
sponsible management by universities of the intellectual
property deriving from their research can be an important
‘up-stream’ intervention. Policies that safeguard end-
product affordability in university agreements on the li-
censing of intellectual property rights – socially respon-
sible licensing (SRL) policies – have had demonstrated
successes in Canada and the United States [39, 40].
The low prevalence of SRL policies (Table 2) among
United Kingdom universities likely reflects lack of
awareness of these approaches in the United Kingdom.
In the United States, most top universities have signed
statements committing to SRL [12–14]; United Kingdom
universities appear to be lagging behind their United
States counterparts. No correlation was found between
proportional ND or hLLMIC funding and SRL licensing
practices (Additional file 3). Nevertheless, three out of
the top four universities by funding for ND research
(Table 1) have publicly available SRL policies, and the
fourth of those (LSHTM) has reported plans to endorse
SRL within 1 year. One explanation may be that univer-
sities that conduct more ND research are more aware of
developments in policy related to treatment access such
as SRL. Another factor may be that these four univer-
sities are relatively highly funded and have larger TTOs,
and are therefore more likely to be aware of newer pol-
icy trends, than most others.
As these provisions are conceptually new, the two uni-
versities reporting 81–100% of licenses containing access
provisions are of particular interest (University of Aber-
deen; University of Oxford). Case studies of practices at
these universities would offer useful insight into the
wider United Kingdom implementation, in line with the
recent recommendations of the All-Party Parliamentary
Group on Global Tuberculosis [15]. The lack of statis-
tical significance of the positive correlations found
between the presence of an SRL policy and both non-
exclusive licensing and access provisions (Table 3) could
be due to the relatively low number of universities that
have adopted such a policy. The technology transfer
office at UCL has indicated that the adoption of an SRL
policy increased their ability to negotiate inclusion of
provisions that promote affordability in licensing agree-
ments [41].
Where SRL policies have been adopted, transparency
and accountability mechanisms in the implementation of
these policies remain important [13]. Further research
on the eventual fate of health products developed in
United Kingdom universities would be valuable, for
example, assessing their availability in resource-poor
settings. In the context of established North American
precedents, and endorsement by the Consultative Expert
Working Group and other bodies, we expect both
universities and funders of research in the United Kingdom
to develop plans for implementing SRL policies more
widely in the near future.
The proportion of health-related research articles
published as free-access (76%) is similar to reported
average European rates [42]. The low variability (IQR
16%) between universities shows that open-access adop-
tion is fairly uniform, likely due to effective advocacy for
policy adoption and increasing requirements for, and sup-
port of, open-access publication by funders. Increasingly,
funders also require publishing with a CC-BY license [43].
CC-BY licensing, allowing free reuse of the published
material with no restrictions other than a requirement of
appropriate attribution, is considered superior to free-
access publication alone [17]. In this regard, there is a
considerable gap in proportion published as free-access
versus CC-BY – 76% versus 23%, respectively. The top four
institutions by THRF – Oxford, Cambridge, UCL, and Im-
perial – are not, overall, highly ranked in proportional CC-
BY publications, spread over a range of 16% to 24% (Fig. 3),
and we found no correlation between total research funding
and free-access or CC-BY publishing. In the United
Kingdom, the adoption of open-access publishing in health
research is not being led by larger institutions.
The finding that proportional hLLMIC research fund-
ing was significantly correlated to both proportional
free-access and CC-BY publishing (r = 0.588, P = 0.004
and r = 0.491, P = 0.02) merits further investigation. A
potential causal mechanism may be that funders that
preferentially fund hLLMIC research have stronger
open-access policies attached to grants. The interactions
between funders and open-access publishing are, how-
ever, beyond the scope of this study.
In Braveman’s equity framework, open-access publish-
ing and SRL policies contribute to an equitable health
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research system by both ‘sharing progress’ and by ‘level-
ling up’ – bringing everyone to the highest standard, in-
stead of reducing standards for those experiencing the
best opportunities.
Our measures of global health research and research
sharing have limitations. Financial expenditure is an im-
perfect measure of research output. This study may not
have captured all global health work being undertaken at
the universities surveyed due to limitations in time
frame, the level of detail provided in databases and the
use of proxy definitions for ‘global health’ (ND and
hLLMIC). The attribution of full grant amount to the
lead institution, in cases where multiple collaborators
were named, has the potential bias of rewarding larger
institutions with larger administrative capacity, and thus
skewing the distribution towards larger institutions
(except for EC grants, where it was possible to separate
the amount to lead institution).
Data based on responses to surveys and FOI requests
must be treated with caution due to potentially variable
interpretation of certain terms; in particular, ‘provisions
that promoted access’ were not defined and respondents
were asked to respond based on what their understanding
of the phrase was. This study did not conduct detailed
analysis of university policies on open-access publishing
and intellectual property management. As both types of
policies can vary greatly in breadth, strength and specific
mechanisms mandated, further analysis of these policies is
eagerly awaited.
Conclusion
Global health research in United Kingdom universities is
concentrated in a small number of institutions and is
generally underfunded as an area of health research,
considering the global burden of disease that it repre-
sents. NDs represent 13.8% of the global burden of
disease but only 6.7% of all health research funding [10].
Between individual universities, the median proportion of
THRF attributable to ND research (2.6%) was five times
below what would be expected given the proportion of
global disease burden they represent (13.8%) [10]. For
research on hLLMICs, both proportional indicators were
even lower (proportion of THRF – 3.7%, median propor-
tion between universities – 1.7%). Most universities lack
socially responsible licensing policies (18 of 25), and do
not license their intellectual property in a way that is likely
to encourage access in resource-poor settings. The
majority of research publications (77%) are not licensed
with gold-standard open access, despite most universities
(15 of 25) having open access policies in place. To meet a
globally equitable level of global health research, where
research funding distribution is commensurate with the
global burden of disease, funders and universities would
need to expand their research activity in global health.
Advocacy is needed to promote the adoption of SRL
policies at United Kingdom universities, with subsequent
follow-up on effective implementation. While open-access
policies are widespread, CC-BY open-access publication is
still far from the norm. For a health research system to be
equitable, progress must be shared by allowing everyone
to enjoy the highest possible standard: to stand on the
shoulders of giants. To this end, there is a need for
increased commitments among United Kingdom univer-
sities to policies that safeguard the affordability of health-
care products and the accessibility of research papers.
Endnotes
1The Budapest Open Access Initiative defines open ac-
cess thus: “By ‘open access’ to [peer-reviewed research lit-
erature], we mean its free availability on the public
internet, permitting any users to read, download, copy,
distribute, print, search, or link to the full texts of these
articles, crawl them for indexing, pass them as data to
software, or use them for any other lawful purpose, with-
out financial, legal, or technical barriers other than those
inseparable from gaining access to the internet itself. The
only constraint on reproduction and distribution, and the
only role for copyright in this domain, should be to give
authors control over the integrity of their work and the
right to be properly acknowledged and cited” [17].
2Although it was one of the top 25 recipients of MRC
funding 2010–2011, the Babraham Institute was excluded
due to not being a university, despite offering post-graduate
programmes as a partner of the University of Cambridge.
Further, the authors recognise the Liverpool School of
Tropical Medicine as a major contributor to global health
and neglected disease research in the United Kingdom, al-
though it does not rank within the top 25 United Kingdom
universities by MRC funding in 2010–2011.
31 EUR = 0.842745667 GBP; 1 USD = 0.631429333 GBP.
4Patent Cooperation Treaty applications that had not
yet matured into national and/or regional applications
were excluded from calculations of the percentage.
5A date range of 12–24 months prior to the data col-
lection date was adopted to avoid missing PMC-archived
articles under a full-text embargo period of up to 1 year.
6For the University of Leeds, a single £7.5 million grant
(for the COMDIS-HSD consortium, http://comdis-hsd.leeds.
ac.uk/) for hLLMIC research represented 23.3% of their total
health research funding in 2011–2014.
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